(PDF) MA15.06 Circulating Tumor DNA Portrays the Resistance

MA15.06 Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.443

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib

Scientific Reports

Multidisciplinary

English

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

Laboratory Investigation

Forensic Medicine

Molecular Biology

English

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

Cancer Research

Cancer Research

English

Overcoming Acquired Resistance to AZD9291, a Third Generation EGFR Inhibitor, Through Modulation of MEK/ERK-dependent Bim and McL-1 Degradation

Clinical Cancer Research

Cancer Research

English

EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment

JCO Precision Oncology

Cancer Research

English

Circulating Methylated DNA: A New Generation of Tumor Markers

Clinical Cancer Research

Cancer Research

English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

Annals of Oncology

English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy

English

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research

Cancer Research

English